Comparative single-cell analysis reveals heterogeneous immune landscapes in adenocarcinoma of the esophagogastric junction and gastric adenocarcinoma
Open Access
- 5 January 2024
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (1) , 1-11
Abstract
Adenocarcinoma of the esophagogastric junction (AEG) is a type of tumor that arises at the anatomical junction of the esophagus and stomach. Although AEG is commonly classified as a subtype of gastric adenocarcinoma (GAC), the tumor microenvironment (TME) of AEG remains poorly understood. To address this issue, we conducted single-cell RNA sequencing (scRNA-seq) on tumor and adjacent normal tissues from four AEG patients and performed integrated analysis with publicly available GAC single-cell datasets. Our study for the first time comprehensively deciphered the TME landscape of AEG, where heterogeneous AEG malignant cells were identified with diverse biological functions and intrinsic malignant nature. We also depicted transcriptional signatures and T cell receptor (TCR) repertoires for T cell subclusters, revealing enhanced exhaustion and reduced clone expansion along the developmental trajectory of tumor-infiltrating T cells within AEG. Notably, we observed prominent enrichment of tumorigenic cancer-associated fibroblasts (CAFs) in the AEG TME compared to GAC. These CAFs played a critical regulatory role in the intercellular communication network with other cell types in the AEG TME. Furthermore, we identified that the accumulation of CAFs in AEG might be induced by malignant cells through FGF-FGFR axes. Our findings provide a comprehensive depiction of the AEG TME, which underlies potential therapeutic targets for AEG patient treatment.Keywords
Funding Information
- Natural Science Foundation of Guangdong Province (2020A1515010573)
This publication has 30 references indexed in Scilit:
- The single-cell transcriptional landscape of mammalian organogenesisNature, 2019
- Adenocarcinoma of the esophagogastric junction and its background mucosal pathology: A comparative analysis according to Siewert classification in a Japanese cohortCancer Medicine, 2018
- Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLLBlood, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMolecular Cancer Therapeutics, 2015
- Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomasBMC Cancer, 2015
- Epidemiology and Risk Factors for Gastroesophageal Junction Tumors: Understanding the Rising Incidence of This DiseaseSeminars in Radiation Oncology, 2013
- Adenocarcinomas of the Esophagogastric Junction Are More Likely to Respond to Preoperative Chemotherapy than Distal Gastric CancerAnnals of Surgical Oncology, 2011
- Fibroblast growth factor signalling: from development to cancerNature Reviews Cancer, 2010